Gastroparesis Management and Opioid Contraindication

Mechanisms of Opioid Contraindication

Opioids, including oxycodone in Percocet, directly impair gastrointestinal motility and are specifically identified as medications that should be withdrawn in gastroparesis patients, as recommended by the American Diabetes Association 1, 2

The American Gastroenterological Association recommends tricyclic antidepressants (TCAs) such as amitriptyline (25-100 mg/day), imipramine (25-100 mg/day), desipramine (25-75 mg/day), and nortriptyline (25-100 mg/day) for pain management in gastroparesis patients 3, 4, 5
Serotonin and norepinephrine reuptake inhibitors (SNRIs) like duloxetine (60-120 mg/day) are effective for visceral pain in gastroparesis, according to the American Gastroenterological Association 3, 4
Anticonvulsants such as gabapentin (>1200 mg/day) and pregabalin (100-300 mg/day) are recommended for pain management in gastroparesis patients by the American Gastroenterological Association 3, 4

The American Diabetes Association recommends identifying the predominant symptom and targeting therapy accordingly when treating pain in gastroparesis 6, 7
Tertiary amine TCAs have more sedating side effects than secondary amines, and anticholinergic side effects may be dose-limiting, especially in patients ≥65 years of age, as noted by the American Geriatrics Society 3, 8
Metoclopramide is the only FDA-approved medication specifically for gastroparesis, but should be used cautiously due to risk of extrapyramidal side effects, as recommended by the American Gastroenterological Association 1, 9
Non-pharmacological approaches, including dietary modifications (small, frequent meals with low fat and fiber content), are recommended by the American Diabetes Association for gastroparesis management 1, 9